Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-063 in Acute Exacerbation of Schizophrenia
NCT02477020Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing TAK-063 20 mg with Placebo (2 arms). Primary endpoint: Positive and Negative Symptom Scale Total at 6 weeks. Started Jul 2015; status: completed.
02
Drugs
balipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02477020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477020.